At the time of writing, Quest Diagnostics, Inc. [DGX] stock is trading at $129.74, up 0.24%. An important factor to consider is whether the stock is rising or falling in short-term value. The DGX shares have gain 4.20% over the last week, with a monthly amount glided 2.37%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 6, March 2024, Phlebotomist’s Actions Keep One Patient Coming Back. In a post published today on Yahoo Finance, A patient who goes often to a Patient Service Center (PSC) in Southern California had a special compliment for a colleague who’s been at Quest for nearly 2 decades.
From an analyst’s perspective:
Quest Diagnostics, Inc. [NYSE: DGX] stock has seen the most recent analyst activity on February 26, 2024, when Leerink Partners initiated its Market Perform rating and assigned the stock a price target of $135. Previously, Jefferies upgraded its rating to Buy on February 07, 2024, and elevated its price target to $155. On January 03, 2024, Barclays initiated with a Equal Weight rating and assigned a price target of $145 on the stock. BofA Securities upgraded its rating to a Buy and increased its price target to $160 on December 12, 2023. Piper Sandler initiated its recommendation with a Neutral. BofA Securities downgraded its rating to Neutral for this stock on May 02, 2023, and downed its price target to $148. In a note dated April 03, 2023, Citigroup upgraded an Neutral rating on this stock and boosted its target price from $125 to $142.
For the past year, the stock price of Quest Diagnostics, Inc. fluctuated between $119.59 and $148.62. Currently, Wall Street analysts expect the stock to reach $155.5 within the next 12 months. Quest Diagnostics, Inc. [NYSE: DGX] shares were valued at $129.74 at the most recent close of the market. An investor can expect a potential return of 19.86% based on the average DGX price forecast.
Analyzing the DGX fundamentals
According to Quest Diagnostics, Inc. [NYSE:DGX], the company’s sales were 9.25B for trailing twelve months, which represents an -1.93% plunge. Gross Profit Margin for this corporation currently stands at 0.33% with Operating Profit Margin at 0.14%, Pretax Profit Margin comes in at 0.12%, and Net Profit Margin reading is 0.09%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 0.14 and Total Capital is 0.11. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.77.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 128.84 points at the first support level, and at 127.94 for the second support level. However, for the 1st resistance point, the stock is sitting at 130.26, and for the 2nd resistance point, it is at 130.78.
Quest Diagnostics, Inc. [DGX] reported earnings per share of $2.15 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $2.11/share, meaning a difference of $0.04 and a surprise factor of 1.90%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $2.22 per share as compared to estimates of $2.19 per share, a difference of $0.03 representing a surprise of 1.40%.
Ratios To Look Out For
It is important to note that Quest Diagnostics, Inc. [NYSE:DGX] has a current ratio of 1.31. On the other hand, the Quick Ratio is 1.20, and the Cash Ratio is 0.38. Considering the valuation of this stock, the price to sales ratio is 1.55, the price to book ratio is 2.28 and price to earnings (TTM) ratio is 17.33.
Transactions by insiders
Recent insider trading involved PREVOZNIK MICHAEL E, SVP & General Counsel, that happened on Feb 29 ’24 when 5611.0 shares were sold. EVP, Regional Businesses, Doherty Catherine T. completed a deal on Feb 29 ’24 to sell 1187.0 shares. Meanwhile, EVP, Regional Businesses Doherty Catherine T. sold 5557.0 shares on Feb 28 ’24.
